<Editors' Choice> Comparison of clinical features between patients with acute exacerbation of idiopathic interstitial pneumonia and collagen vascular disease-associated interstitial pneumonia.
Charlson Comorbidity Index score
acute exacerbation
collagen vascular disease-associated interstitial pneumonia
idiopathic interstitial pneumonia
lactate dehydrogenase
Journal
Nagoya journal of medical science
ISSN: 2186-3326
Titre abrégé: Nagoya J Med Sci
Pays: Japan
ID NLM: 0412011
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
25
03
2022
accepted:
04
11
2022
medline:
13
10
2023
pubmed:
13
10
2023
entrez:
13
10
2023
Statut:
ppublish
Résumé
Acute exacerbation (AE) of interstitial pneumonia (IP) shows poor prognosis, due to the typical histological pattern of diffuse alveolar damage superimposed upon lung fibrosis. The previous reports comparing clinical features between AE of idiopathic interstitial pneumonias (IIPs) and those of IPs with known etiology are limited. We retrospectively compared clinical parameters including age, sex, Charlson Comorbidity Index score (CCIS), blood biomarkers at diagnosis of AE, treatment, and 3-month mortality between patients with AE of IIPs and collagen vascular disease-associated interstitial pneumonia (CVD-IP). We assessed 85 patients, comprising 66 patients with AE of IIPs (78%) and 19 patients with AE of CVD-IP (22%). The least absolute shrinkage and selection operator regression selected CCIS (hazard ratio, 1.281; 95% confidence interval, 1.055-1.556; P = 0.012) and log serum lactate dehydrogenase (LDH) (hazard ratio, 6.267; 95% confidence interval, 2.172-18.085; P < 0.001) as significant predictors of 3-month mortality among these patients. Also, the adjusted survival curves using sex, CCIS, and serum LDH showed no significant differences between these two groups. In conclusion, among AE patients, CCIS and serum LDH level may be more important prognostic factors for 3-month mortality rather than two classification of IP subtypes: IIPs and CVD-IP.
Identifiants
pubmed: 37829474
doi: 10.18999/nagjms.85.3.602
pmc: PMC10565576
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
602-611Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest with respect to this study.
Références
Can Respir J. 2004 Mar;11(2):117-22
pubmed: 15045042
Clin Respir J. 2021 Mar;15(3):336-344
pubmed: 33197284
J Clin Med. 2021 Feb 18;10(4):
pubmed: 33670776
Acta Radiol. 2003 May;44(3):258-64
pubmed: 12751995
Respiration. 2012;83(1):20-7
pubmed: 21912082
Intern Med. 2017;56(6):621-626
pubmed: 28321059
Chest. 2007 Jul;132(1):214-20
pubmed: 17400667
Respir Res. 2016 Jul 11;17(1):79
pubmed: 27401332
PLoS One. 2016 Mar 29;11(3):e0151425
pubmed: 27023440
Crit Care Med. 2005 Oct;33(10):2228-34
pubmed: 16215375
J Thorac Dis. 2020 Oct;12(10):5774-5782
pubmed: 33209409
Respir Res. 2014 Sep 01;15:109
pubmed: 25176016
Eur Respir J. 2006 Jan;27(1):143-50
pubmed: 16387947
Eur Respir J. 2011 Feb;37(2):356-63
pubmed: 20595144
Chest. 2007 Nov;132(5):1652-8
pubmed: 17998366
Am J Respir Crit Care Med. 2007 Oct 1;176(7):636-43
pubmed: 17585107
Respir Med. 2009 Jun;103(6):846-53
pubmed: 19181509
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Lung. 2014 Feb;192(1):141-9
pubmed: 24221341
J Thorac Dis. 2019 Jun;11(6):2448-2457
pubmed: 31372282
Eur Respir J. 2008 Jul;32(1):170-4
pubmed: 18256070
BMJ Open. 2013 Jul 31;3(7):
pubmed: 23903809
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620935774
pubmed: 32600180
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
JAMA. 1968 Jun 24;204(13):1193-5
pubmed: 5694700